Arcutis Biotherapeutics (ARQT) Change in Receivables (2022 - 2026)

Arcutis Biotherapeutics' Change in Receivables history runs 5 years deep, the most recent figure standing at -$1.9 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 115.0% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at $59.0 million (up 22.17% YoY), while the FY2025 annual figure was $73.2 million, up 54.81% from the prior year.
• Change in Receivables for Q1 2026 stood at -$1.9 million, down from $31.1 million in the prior quarter.
• The five-year high for Change in Receivables was $31.1 million in Q4 2025, with the low at -$1.9 million in Q1 2026.
• The 5-year median for Change in Receivables is $6.4 million (2023), against an average of $9.6 million.
• The sharpest annual moves came in 2024 and 2026: Change in Receivables surged 651.54% in 2024, then slumped 115.0% in 2026.
• Arcutis Biotherapeutics' Change in Receivables stood at $6.0 million in 2022, then gained by 6.02% to $6.4 million in 2023, then surged by 121.06% to $14.1 million in 2024, then surged by 120.25% to $31.1 million in 2025, then sank by 105.95% to -$1.9 million in 2026.
• Business Quant data shows ARQT's Change in Receivables at -$1.9 million in Q1 2026, $31.1 million in Q4 2025, and $8.4 million in Q3 2025.